Thousand oaks-based biotech giant Amgen reported a steep increase in second quarter earnings per share on higher product sales and strong performance from its newer products. Earnings per share rose 20 percent compared to the previous second quarter to $3.48 after share buybacks and a lower tax rate compared to 2017. Repatha sales grew nearly…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
